Company intelligence / Profile preview
StemMed
Houston, Texas, United Statesstemmedcancer.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
StemMed develops novel therapeutics targeting tumorigenic stem cells—especially those driving breast cancer—and offers state-of-the-art preclinical drug testing using diverse patient-derived xenograft models. Their lead scientific focus includes targeting STAT3 to inhibit tumor growth, with a belief that this approach may be particularly effective against cancers resistant to conventional therapies. No clinical trial results are reported.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculePre-clinical drug testing services
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on StemMed.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on StemMed.